Journey Medical Corporation - Common Stock — 四半期キャッシュフロー (NASDAQ:DERM) | MetaTrader

チャート全体を表示 Full chart

Financials

概要明細書統計

総資産 80.24 M84.96 M81.16 M85.19 M94.59 M91.53 M 負債合計 60.17 M63.42 M61.91 M59.29 M62.74 M60.7 M 純資産合計 20.07 M21.54 M19.25 M25.9 M31.85 M30.83 M 負債および純資産合計 80.24 M84.96 M81.16 M85.19 M94.59 M91.53 M 有利子負債合計 24.88 M23.11 M25.11 M25.16 M25.28 M25.37 M 純負債 24.88 M23.11 M1.07 M-5.41 M1.19 M-1.85 M

ニュース

Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO)

Here's What Key Metrics Tell Us About Journey Medical (DERM) Q1 Earnings

Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates

Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates

Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates

Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know

Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?

Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript

B.Rileyはジャーニー・メディカル株に対する「買い」評価を維持、目標価格12ドルを据え置き

B.Riley reiterates Buy rating on Journey Medical stock, maintains $12 target

Journey Medical Stock: Emrosi Is Winning, But The Stock Hasn't Noticed (NASDAQ:DERM)

フォートレス・バイオテック社のメンケス病治療薬、FDAが新たなPDUFA期日を設定